BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Nuvilex Phase III Clinical Trials in Strong Hands With Dr. Gerald Crabtree


4/1/2013 8:49:43 AM

NEW YORK, NY--(Marketwire - April 01, 2013) - Nuvilex, Inc. (OTCQB: NVLX) CEO, Dr. Robert Ryan knew exactly what he was doing two years ago when he announced Dr. Gerald Crabtree would be joining his team as the company's Chief Operating Officer (COO). Stock House Group, a full service investment relations firm focused on research, awareness and content development spoke with Dr. Crabtree and agrees he is the right guy, at the right place, at the right time, and his extensive expertise should help carry this small biotech across the finish line.

Dr. Gerald Crabtree has spent more than forty of his 72 years studying cancer in one way or another -- from his time at Brown University from 1970-1985, a period that included work in the early 1980s at the Roger Williams Cancer Center on the clinical development of a cancer drug that was further developed by Eli Lilly, to his time in the 1990s with Bristol-Myers Squibb as part of the team that developed Taxol, a more than $11-billion drug for the company.

Dr. Crabtree has worked with a number of companies, each time finding himself in a crucial role in the company's cancer research, development, and in many cases, its clinical trials, and says each experience has helped shape his understanding of the complex disease. "I have been blessed to have known and worked with some of the major players in the cancer field and to have been involved in the development of a major cancer drug like Taxol. But now, I am involved with something that may dwarf all of those achievements."

And, that something is Nuvilex's unique and proprietary cell encapsulation or "Cell-in-a-Box" technology. The company has gone all in on "Cell-in-a-Box" with almost $30-million invested in the technology and landing Dr. Crabtree to help drive the success on its first big chance to show off in a large-scale Phase III clinical trial.

Continue reading the rest of this article at www.stockhousegroup.com/features

About Stock House Group

Stock House Group is a full service Investment Relations firm specializing in Awareness, Research, and Content Development. The firm offers a platform to CEOs to develop their story through the press, Research Reports, and CEO Interviews. At the same time, we're building a library of Research to assist Investors in their due diligence on small and large cap stocks.


Contact:
Stock House Group
www.stockhousegroup.com
Email Contact
646-397-4020

Digg this    Bookmark with del.icio.us    Add to Newsvine

Technorati:



Read at BioSpace.com

Nuvilex
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES